GoAI
Get started
3D Medicines Inc. logo

3D Medicines Inc.

1244.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$3.05

−HK$0.095 · -3.02%

Aug 25, 4:08 PM HKT

1244.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Zhaolong Gong
Listed since
Dec 15, 2022
Employees
162

Market position

Day range

Current HK$3.05

52-week range

Current HK$3.05

Open
HK$3.10
Previous close
HK$3.145
Volume
256.5K
1.09× average
Average volume
235.5K
Average daily volume
Market cap
750.06M HKD
Beta
0.25
Market reference 1
50-day average
HK$2.3825
+28.02% above average
200-day average
HK$3.8104
-19.96% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.16B CNY
P/E (TTM)
-3.63×
P/B (TTM)
1.08×
P/S (TTM)
1.81×
EV / EBITDA
-5.86×
Earnings yield
-15.11%
Free cash flow yield
-12.75%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
83.96%
Operating margin
-31.64%
Net margin
-49.86%
Return on equity
-29.74%
Return on assets
-18.95%
Return on invested capital
-16.14%

Financial health

Debt / equity
0.26×
Current ratio
1.45×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends340%-649%-1638%-2627%Gross margin, FY2021: 92.90%Gross margin, FY2022: 92.56%Gross margin, FY2023: 82.53%Gross margin, FY2024: 83.42%Gross margin, FY2025: 83.96%Operating margin, FY2021: -856.71%Operating margin, FY2022: -68.06%Operating margin, FY2023: -78.31%Operating margin, FY2024: -27.70%Operating margin, FY2025: -31.64%Net margin, FY2021: -2379.84%Net margin, FY2022: -180.54%Net margin, FY2023: -82.64%Net margin, FY2024: -40.99%Net margin, FY2025: -49.86%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 92.90%. Gross margin FY2022 92.56%. Gross margin FY2023 82.53%. Gross margin FY2024 83.42%. Gross margin FY2025 83.96%. Operating margin FY2021 -856.71%. Operating margin FY2022 -68.06%. Operating margin FY2023 -78.31%. Operating margin FY2024 -27.70%. Operating margin FY2025 -31.64%. Net margin FY2021 -2379.84%. Net margin FY2022 -180.54%. Net margin FY2023 -82.64%. Net margin FY2024 -40.99%. Net margin FY2025 -49.86%.

Income trends

Revenue

356.09M CNY-20.10%

Operating income

−112.65M CNY+8.73%

Net income

−177.53M CNY+2.81%
Income trends across reported periods841.85M CNY14.24M CNY−813.38M CNY−1.64B CNYRevenue, FY2021: 60.26M CNYRevenue, FY2022: 567.39M CNYRevenue, FY2023: 634.95M CNYRevenue, FY2024: 445.65M CNYRevenue, FY2025: 356.09M CNYOperating income, FY2021: −516.25M CNYOperating income, FY2022: −386.17M CNYOperating income, FY2023: −497.25M CNYOperating income, FY2024: −123.43M CNYOperating income, FY2025: −112.65M CNYNet income, FY2021: −1.43B CNYNet income, FY2022: −1.02B CNYNet income, FY2023: −524.7M CNYNet income, FY2024: −182.66M CNYNet income, FY2025: −177.53M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 60.26M CNY. Revenue FY2022 567.39M CNY. Revenue FY2023 634.95M CNY. Revenue FY2024 445.65M CNY. Revenue FY2025 356.09M CNY. Operating income FY2021 −516.25M CNY. Operating income FY2022 −386.17M CNY. Operating income FY2023 −497.25M CNY. Operating income FY2024 −123.43M CNY. Operating income FY2025 −112.65M CNY. Net income FY2021 −1.43B CNY. Net income FY2022 −1.02B CNY. Net income FY2023 −524.7M CNY. Net income FY2024 −182.66M CNY. Net income FY2025 −177.53M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue356.09M CNY445.65M CNY634.95M CNY567.39M CNY60.26M CNY
Cost of goods sold57.12M CNY73.91M CNY110.94M CNY42.22M CNY4.28M CNY
Gross profit298.97M CNY371.74M CNY524.01M CNY525.18M CNY55.98M CNY
Research and development156.1M CNY180.72M CNY425.5M CNY350.86M CNY371.16M CNY
Selling, general, and administrative255.52M CNY314.45M CNY595.89M CNY500.49M CNY193.79M CNY
Operating expenses411.62M CNY495.17M CNY1.02B CNY846.54M CNY559.07M CNY
Interest income20.33M CNY10.92M CNY6.53M CNY7.21M CNY5.5M CNY
Interest expense5.09M CNY9.5M CNY7.77M CNY3.11M CNY1.53M CNY
Depreciation and amortization8.91M CNY7.86M CNY25.46M CNY21.6M CNY12.59M CNY
Operating income−112.65M CNY−123.43M CNY−497.25M CNY−386.17M CNY−516.25M CNY
Net income−177.53M CNY−182.66M CNY−524.7M CNY−1.02B CNY−1.43B CNY

Company facts updated Aug 25, 2026.

Earnings

Latest fiscal-year EPS
-0.72
FY2025
Latest fiscal-year revenue
356.09M CNY
FY2025 · -20.10% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend2.88-11.52-25.92-40.32FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend692.42M462.54M232.67M2.79MFY21FY22FY23FY24FY25

1244.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$204.2

+3.29%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

+0.09%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$223.2

+0.81%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$52.20

+7.41%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.58

+1.67%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.1

+0.60%

Continue in GoAI

Research 1244.HK

research.disclaimer